Aviso: Este site agrega dados públicos oficiais da FDA, ClinicalTrials.gov, PubMed e SEC EDGAR apenas para referência geral. Não constitui aconselhamento médico, diagnóstico, recomendação de tratamento ou aconselhamento de investimento.

PubMed

Focal High-Intensity Focused Ultrasound Ablation of the Prostate.

PMID: 34499554 · 2021

L, a, u, r, e, n, , R, , A, b, r, a, m, s, ;, , M, i, c, h, a, e, l, , O, , K, o, c, h, ;, , C, l, i, n, t, o, n, , D, , B, a, h, l, e, r

RevistaJournal of endourology
Ano2021
PMID34499554

Resumo

With the advancement of early detection tools for prostate cancer and ability to better localize disease, there has been increased interest in focal or targeted therapies that carry less morbidity than traditional whole-gland treatments. The Sonablate® high-intensity focused ultrasound (HIFU) device has Food and Drug Administration (FDA) 510(K) clearance in the United States for ablation of prostate tissue. HIFU utilizes an ultrasound (US) transducer that focuses US beams on a preset point as mu

Fonte oficial

Ver no PubMed →

Dados provenientes do PubMed / NCBI. Para consultar o texto integral e as informações mais recentes, recorra sempre ao registo oficial.

↑